Companies Backed by Anthos Capital
4 companies in Anthos Capital's investment portfolio.
Back to Anthos Capital profileInvestment Thesis
“Invests in growth-stage healthcare and technology companies with focus on transformative healthcare solutions.”
Portfolio Companies (2)
10x Genomics
10x Genomics makes instruments, consumables and software for single-cell and spatial biology research. It went public on Nasdaq (TXG) in September 2019 and reported $642.8 million of revenue for 2025.
Veracyte
Veracyte is a South San Francisco genomic diagnostics company whose tests cover thyroid, prostate, breast and lung cancer. It went public on Nasdaq (VCYT) in October 2013 and reported $517M in revenue for 2025.
Other Investments (2)
Portfolio Analysis
Anthos Capital has built a portfolio of 4 companies across 1 sector, including Biotech. Of these investments, 2 have achieved successful exits through acquisitions or IPOs, demonstrating the firm's track record of backing companies to meaningful outcomes.
The portfolio reflects investments across the IPO stage, showing Anthos Capital's approach to supporting companies at a focused stage of development.
Frequently Asked Questions
How many companies has Anthos Capital invested in?
Anthos Capital has invested in 4+ companies across 1 different sectors. Of these, 2 have achieved successful exits through acquisitions or IPOs.
What sectors does Anthos Capital invest in?
Anthos Capital's portfolio spans Biotech. This diversification reflects the firm's broad investment thesis and sector expertise.
What stages does Anthos Capital invest at?
Anthos Capital invests across the IPO stage. Their portfolio includes companies at various points in their growth journey.
How many exits has Anthos Capital had?
Anthos Capital has had 2 portfolio companies achieve exits through acquisitions or IPOs. This track record of exits demonstrates the firm's ability to identify and support companies through successful outcomes.
Archstone
Building your first fund? Run it like an institution.
Fund admin, LP portal, capital calls, distributions, and reporting in one place. Purpose-built for emerging fund managers. Starting at $297/mo.
See Archstone